Zephyr® Endobronchial Valve Treatment

The Outcomes, The Evidence, The Lives Changed

April 10, 2024
6:00 P.M. ET / 3:00 P.M. PT

Please join this webinar to learn more about the following:

  • Treatment mechanism of action & patient experience
  • Clinical evidence, patient outcomes, potential risks
  • Patient eligibility and screening procedures
  • Patient management strategies 
Deborah Stahlnecker Headshot

Deborah Stahlnecker, DO, FCCP

Director, Interventional Pulmonary
Medical Director, Anderson ICU
St. Luke’s Pulmonary and Critical Care Associates

Thomas Zanders Headshot

Thomas B. Zanders, DO, FACP

Program Director, Pulmonary & Critical Care Medicine Fellowship
Medical Director, Medical Intensive Care Unit Bethlehem Campus
St. Luke’s Pulmonary and Critical Care Associates

Please Register Below

The Zephyr Endobronchial Valve is a clinically-proven Bronchoscopic treatment for patients with severe COPD/emphysema who suffer from dyspnea despite optimized medical therapy.

Over 25,000 patients have been treated globally.  The GOLD Report has included Endobronchial Valve Treatment an Evidence “A” intervention since 2020.

  • By submitting this form, I consent to Pulmonx Corporation (“Pulmonx”) and its third-party vendors using the information I have provided to contact me (via phone, email or text) with information regarding its products, inform me regarding various news, events and research studies and to allow Pulmonx to use this information for additional purposes identified in its Privacy Policy.

  • Hidden
    MM slash DD slash YYYY


Physicians are paid consultants of Pulmonx Corporation.

© 2023 Pulmonx Corp or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation and its affiliates.
US-EN-1896-v2

Privacy Preference Center

Privacy Preferences